EMBRAMINE TEOCLATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H22BrNO.C7H7ClN4O2
Molecular Weight	562.886
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C)(C3=CC=CC=C3)C4=CC=C(Br)C=C4

InChI

InChIKey=UZJKOLCOUILXEJ-UHFFFAOYSA-N

InChI=1S/C18H22BrNO.C7H7ClN4O2/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h4-12H,13-14H2,1-3H3;1-2H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C7H7ClN4O2
Molecular Weight	214.609
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H22BrNO
Molecular Weight	348.277
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.medindia.net/doctors/drug_information/embramine.htm | https://www.drugs.com/international/embramine.html | https://www.ncbi.nlm.nih.gov/pubmed/7976789

Embramine or mebrophenhydramine is an antiallergic agent. Embramine is a histamine H₁-receptor antagonist exerting anticholinergic activity. It may inhibit stimulated platelet functions by inhibiting phospholipase A2. It is prescribed for severe allergic conditions.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7758143	Antagonist 2778

PubMed

Title	Date	PubMed
Pharmacological intervention with platelet phospholipase A2.	2001	11802290
Vitrification of mouse oocytes using a nylon loop.	2001 Mar	11170276
Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)).	2002 Feb 15	12031829
Titrimetric and spectrophotometric assay of some antihistamines through the determination of the chloride of their hydrochlorides.	2002 Jan	11902650
H(1)- antihistamines and activated blood platelets.	2006 Apr	16547813

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 25mg, every 4 to 6 hours. Max: 150mg.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:05:09 GMT 2023` Edited by `admin` on `Fri Dec 15 18:05:09 GMT 2023`
Record UNII	C0E85T23QR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMBRAMINE TEOCLATE

Common Name

English

1H-PURINE-2,6-DIONE, 8-CHLORO-3,9-DIHYDRO-1,3-DIMETHYL-, COMPD. WITH 2-(1-(4-BROMOPHENYL)-1-PHENYLETHOXY)-N,N-DIMETHYLETHANAMINE (1:1)

Systematic Name

English

Embramine teoclate [WHO-DD]

Common Name

English

MEDRIN

Brand Name

English

EMBRAMINTEOCLAT

Common Name

English

MEBROPHENHYDRINATE

Common Name

English

Code System Code Type Description

SMS_ID

100000092598